ClinicalTrials.gg
CompletedNCT01491113Updated Feb 10, 2014Results posted

Pharmacokinetic (PK) Study in Japanese Non-epileptic Renal Impaired Patients

A Phase 4 interventional study of Levetiracetam 250 mg and Levetiracetam 500 mg in Healthy Subjects and Renal Impairments, sponsored by UCB Pharma. Completed at 2 sites in Japan. Open to participants aged 20 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-02-10.

Sponsored by UCB Pharma (part of UCB S.A.) · Phase 4, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
20 Years to 80 Years
Sex
All
01

Study summary

This is a human pharmacology, single-dose study to investigate the pharmacokinetics of orally administered Levetiracetam (LEV) in Japanese subjects with normal renal function and in Japanese subjects with various degrees of impaired renal function.

Read the detailed description

The primary objective of this study is to evaluate the plasma and urine PK of Levetiracetam (ucb L059) and its metabolite (ucb L057) after a single dose of LEV 250 mg or LEV 500 mg in Japanese subjects with normal renal function and in Japanese subjects with various degrees of renal impairment.

02

Conditions studied

  • Healthy Subjects
  • Renal Impairments

Keywords

  • Levetiracetam
  • Oral administration
  • Japanese
  • Non-epileptic
  • Healthy
  • Renal impaired subjects
03

In context

Lead sponsor

UCB Pharma is the lead sponsor of 242 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy subjects with normal renal function
  • Subject is Japanese
  • Subjects with within 1 of 3 Groups (CLcr[mL/min/1.73 cm\^2]: Group B: 50 - \<80, Group C: 30 - \<50, Group D: \<30), or for Group E, subjects with end-stage renal failure undergoing hemodialysis

Exclusion criteria

Exclusion Criteria:

  • Subjects has taken any drug treatment, disease or injury to influence Levetiracetam PK except for renal impairments
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Group A: Normal renal function

    Subjects who have normal renal function (CLcr \>80 mL/min/1.73 m\^2). Subjects will be orally administered Levetiracetam (LEV) 500 mg once. After LEV administration, safety assessments and blood and urine samplings will be taken through to Day 4 during the Treatment Period, and safety follow-up assessments will be performed on Day 8 according to the schedule of study assessments. * Blood samples for Pharmacokinetics (PK): Predose (Baseline), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours postdose * Urine samples for PK: 0 - 6, 6 - 12, 12 - 24, 24 - 48, 48 - 72 hours postdose

    Drug: Levetiracetam 500 mg

  • Experimental
    Group B: Mild renal impairment

    Patients who have mild renal impairment (50\<CLcr \<80 mL/min/1.73 m\^2). Subjects will be orally administered (Levetiracetam) LEV 500 mg once. After LEV administration, safety assessments and blood and urine samplings will be conducted through Day 5 during the Treatment Period, and safety follow-up assessments will be performed on Day 8 according to the schedule of study assessments. * Blood samples for Pharmacokinetics (PK): Predose (Baseline), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96 hours postdose * Urine samples for PK: 0 - 6, 6 - 12, 12 - 24, 24 - 48, 48 - 72, 72 - 96 hours postdose

    Drug: Levetiracetam 500 mg

  • Experimental
    Group C: Moderate renal impairment

    Patients who have moderate renal impairment (30\<CLcr \< 50 mL/min/1.73 m\^2). Subjects will be orally administered Levetiracetam (LEV) 250 mg once. After LEV administration, safety assessments and blood and urine samplings will be conducted through Day 6 during the Treatment Period, and safety follow-up assessments will be performed on Day 8 according to the schedule of study assessments. * Blood samples for Pharmacokinetics (PK): Predose (Baseline), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120 hours postdose * Urine samples for PK: 0 - 6, 6 - 12, 12 - 24, 24 - 48, 48 - 72, 72 - 96, 96 -120 hours postdose

    Drug: Levetiracetam 250 mg

  • Experimental
    Group D: Severe renal impairment

    Patients who have severe renal impairment (CLcr \<30 mL/min/1.73 m\^2). Subjects will be orally administered Levetiracetam (LEV) 250 mg once. After LEV administration, safety assessments and blood and urine samplings will be conducted through Day 7 during the Treatment Period, and safety follow-up assessments will be performed on Day 8 according to the schedule of study assessments. * Blood samples for Pharmacokinetics (PK): Predose (Baseline), and 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144 hours postdose * Urine samples for PK: 0 - 6, 6 - 12, 12 - 24, 24 - 48, 48 - 72, 72 - 96, 96 -120, 120 - 144 hours postdose

    Drug: Levetiracetam 250 mg

  • Experimental
    Group E: End-stage renal disease

    Group E will receive Levetiracetam (LEV) 500 mg on Day 1, 44 hours (h) before the first hemodialysis. As a supplementary dose LEV 250 mg will be administered 1 h after the end of the first hemodialysis on Day 3. The 4-h Hemodialysis are scheduled as follows: 1. Dialysis: 44 h to 48 h after the first dose (Day 3) 2. Dialysis: 92 h to 96 h after the first dose (Day 5) 3. Dialysis: 140 h after the first dose (Day 7) Safety assessments and blood samplings will be conducted until Day 7. Safety follow-up assessments will be performed on Day 10. Blood samples for Pharmacokinetics (PK): Predose (Baseline), and 0.5, 1, 2, 4, 6, 8, 12, 24, 30, 44\*, 44.25\*, 44.5\*, 45\*, 46\*, 47\*, 48\*, 49, 49.5, 50, 51, 53, 55, 57, 61, 73, 92, 96, 120, 140 hours post first dosing. 49 h-sample should be taken before the additional dose. The 44 h, 92 h, and 140 h sample should be taken before the start of the hemodialysis. \*Inflow blood, outflow blood, and dialysate fluid will be collected.

    Drug: Levetiracetam 250 mg · Drug: Levetiracetam 500 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of Ucb L059 (LEV) for Groups A to D

    Cmax refers to the maximum observed concentration of L059 (Levetiracetam). Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours

    Time frame: From Baseline up to 144 hours post first dose

  2. Area Under the Concentration-time Curve (AUC(0-t)) of Ucb L059 (LEV) From Baseline to the Last Quantifiable Concentration for Groups A to D

    AUC(0-t) refers to the area under the plasma concentration versus time curve, which provides information on the exposure. Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours

    Time frame: From Baseline up to 144 hours post first dose

  3. Maximum Observed Plasma Concentration (Cmax) of Ucb L057 for Groups A to D

    Cmax refers to the maximum observed concentration of ucb L057. Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours

    Time frame: From Baseline up to 144 hours post first dose

  4. Area Under the Concentration-time Curve (AUC(0-t)) of Ucb L057 From Baseline to the Last Quantifiable Concentration for Groups A to D

    AUC(0-t) refers to the area under the plasma concentration versus time curve, which provides information on the exposure. Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours

    Time frame: From Baseline up to 144 hours post first dose

  5. Maximum Observed Plasma Concentration (Cmax) of Ucb L059 (LEV) for Group E During First Period

    Cmax refers to the maximum observed concentration of ucb L059 (Levetiracetam).

    Time frame: From Baseline to 44 hours post first dose

  6. Area Under the Concentration-time Curve (AUC(0-t)) of Ucb L059 (LEV) From Baseline to 44 Hours for Group E

    AUC(0-t) refers to the area under the plasma concentration versus time curve, which provides information on the exposure.

    Time frame: From Baseline to 44 hours post first dose

  7. Maximum Observed Plasma Concentration (Cmax) of Ucb L057 for Group E During First Period

    Cmax refers to the maximum observed concentration of ucb L057.

    Time frame: From Baseline to 44 hours post first dose

  8. Area Under the Concentration-time Curve (AUC(0-t)) of Ucb L057 From Baseline to 44 Hours for Group E

    AUC(0-t) refers to the area under the plasma concentration versus time curve, which provides information on the exposure.

    Time frame: From Baseline to 44 hours post first dose

Secondary outcomes

  1. Total Amount Excreted in Urine (Ae) of Ucb L059 (LEV) for Groups A to D

    Ae refers to the total amount of ucb L059 (Levetiracetam) excreted in urine. Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours

    Time frame: From Baseline up to 144 hours post first dose

  2. Fraction of Dose Excreted in Urine (fe) of Ucb L059 (LEV) for Groups A to D

    fe refers to the fraction of dose excreted in urine of L059 (Levetiracetam). Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours

    Time frame: From Baseline up to 144 hours post first dose

  3. Renal Clearance (CLR) of Ucb L059 (LEV) for Groups A to D

    Renal clearance describes the removal of drug from a volume of plasma in a given unit of time by the kidneys. Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours

    Time frame: From Baseline up to 144 hours post first dose

  4. Apparent Total Body Clearance (CL/F) of Ucb L059 (LEV) for Groups A to D

    Clearance (expressed as volume/time) describes the removal of drug from a volume of plasma in a given unit of time (drug loss from the body). It indicates the volume of plasma (or blood) from which the drug is completely removed, or cleared, in a given time period. Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours

    Time frame: From Baseline up to 144 hours post first dose

  5. Nonrenal Clearance (CLNR) of Ucb L059 (LEV) for Groups A to D

    The Non-Renal Clearance (CLNR) describes the removal of drug by organs other than the kidneys. Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours

    Time frame: From Baseline up to 144 hours post first dose

  6. Total Amount Excreted in Urine (Ae) of Ucb L057 for Groups A to D

    Ae refers to the total amount of ucb L057 excreted in urine. Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours

    Time frame: From Baseline up to 144 hours post first dose

  7. Renal Clearance (CLR) of Ucb L057 for Groups A to D

    Renal clearance describes the removal of drug from a volume of plasma in a given unit of time by the kidneys. Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours

    Time frame: From Baseline up to 144 hours post first dose

  8. Apparent Total Body Clearance (CL/F) of Ucb L059 (LEV) for Group E During First Period

    Clearance (expressed as volume/time) describes the removal of drug from a volume of plasma in a given unit of time (drug loss from the body). It indicates the volume of plasma (or blood) from which the drug is completely removed, or cleared, in a given time period. Geometric mean and Coefficient of Variation (CV) was not calculated since the extrapolated part of the AUC was greater than 20 %.

    Time frame: From Baseline to 44 hours post first dose

  9. Time to Reach Maximum Plasma Concentration (Tmax) of Ucb L059 (LEV) for Groups A to D

    tmax refers to the time to reach maximum plasma concentration of ucb L059 (Levetiracetam). Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours

    Time frame: From Baseline up to 144 hours post first dose

  10. Area Under the Concentration-time Curve (AUC) of Ucb L059 (LEV) From Baseline to Infinite for Groups A to D

    AUC(0-t) refers to the area under the plasma concentration versus time curve, which provides information on the exposure. Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours

    Time frame: From Baseline up to 144 hours post first dose

  11. Terminal Half-life (t1/2) of Ucb L059 (LEV) for Groups A to D

    Terminal half-life refers to the time it takes for the concentrations to decrease by half. Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours

    Time frame: From Baseline up to 144 hours post first dose

  12. Time to Reach Maximum Plasma Concentration (Tmax) of Ucb L057 for Groups A to D

    tmax refers to the time to reach maximum plasma concentration (tmax). Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours

    Time frame: From Baseline up to 144 hours post first dose

  13. Area Under the Concentration-time Curve (AUC) of Ucb L057 From Baseline to Infinite for Groups A to D

    AUC(0-t) refers to the area under the plasma concentration versus time curve, which provides information on the exposure. Geometric mean and CV was not calculated since the extrapolated part of the AUC was greater than 20 %. Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours

    Time frame: From Baseline up to 144 hours post first dose

  14. Terminal Half-life (t1/2) of Ucb L057 for Groups A to D

    Terminal half-life refers to the time it takes for the concentrations to decrease by half. Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours

    Time frame: From Baseline up to 144 hours post first dose

  15. Time to Reach Maximum Plasma Concentration (Tmax) of Ucb L059 (Levetiracetam) for Group E During First Period

    tmax refers to the time to reach the maximum plasma concentration of ucb L059 (Levetiracetam).

    Time frame: From Baseline to 44 hours post first dose

  16. Area Under the Concentration-time Curve (AUC) of Ucb L059 (LEV) From Baseline to Infinite for Group E

    AUC(0-t) refers to the area under the plasma concentration versus time curve, which provides information on the exposure. Geometric mean and CV was not calculated since the extrapolated part of the AUC was greater than 20 %.

    Time frame: From Baseline to 140 hours post first dose

  17. Terminal Half-life (t1/2) of Ucb L059 (LEV) for Group E During First Period

    Terminal half-life refers to the time it takes for the concentrations to decrease by half. Geometric mean and CV was not calculated since the extrapolated part of the AUC was greater than 20 %.

    Time frame: From Baseline to 44 hours post first dose

  18. Time to Reach Maximum Plasma Concentration (Tmax) of Ucb L057 for Group E During First Period

    tmax refers to the time to reach maximum plasma concentration (tmax).

    Time frame: From Baseline to 44 hours post first dose

  19. Hemodialysis Clearance (CLD) of Ucb L059 (LEV) During First Dialysis for Group E

    Calculated by the Arterio - Venous difference method and cumulative dialysate method.

    Time frame: From 44 hours to 48 hours post first dose

  20. Ultrafiltration Clearance (CLUF) of Ucb L059 (LEV) During First Dialysis for Group E

    Calculated by the Arterio - Venous difference method and cumulative dialysate method.

    Time frame: From 44 hours to 48 hours post first dose

  21. Hemodialysis Clearance (CLHD) of Ucb L059 (LEV) During First Dialysis for Group E

    Calculated according: CLHD=CLD+CLUF.

    Time frame: From 44 hours to 48 hours post first dose

07

Results

Posted Jan 10, 2014

Participant flow

The Participant Flow refers to the Safety Set population which includes all patients that received at least one dose of study medication.

Participant flow — Overall Study
MilestoneGroup A: Normal Renal FunctionGroup B: Mild Renal ImpairmentGroup C: Moderate Renal ImpairmentGroup D: Severe Renal ImpairmentGroup E: End-stage Renal Disease
Started66666
Completed66666
Not completed00000

Outcome measures

PrimaryMaximum Observed Plasma Concentration (Cmax) of Ucb L059 (LEV) for Groups A to D

Cmax refers to the maximum observed concentration of L059 (Levetiracetam). Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours

Time frame:
From Baseline up to 144 hours post first dose
Reported as:
Geometric mean · µg/mL
Maximum Observed Plasma Concentration (Cmax) of Ucb L059 (LEV) for Groups A to D
µg/mLGroup A: Normal Renal FunctionGroup B: Mild Renal ImpairmentGroup C: Moderate Renal ImpairmentGroup D: Severe Renal Impairment
Maximum Observed Plasma Concentration (Cmax) of Ucb L059 (LEV) for Groups A to D21.9357 ± 31.215.5334 ± 25.310.7767 ± 24.39.1754 ± 30.4
PrimaryArea Under the Concentration-time Curve (AUC(0-t)) of Ucb L059 (LEV) From Baseline to the Last Quantifiable Concentration for Groups A to D

AUC(0-t) refers to the area under the plasma concentration versus time curve, which provides information on the exposure. Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours

Time frame:
From Baseline up to 144 hours post first dose
Reported as:
Geometric mean · h*µg/mL
Area Under the Concentration-time Curve (AUC(0-t)) of Ucb L059 (LEV) From Baseline to the Last Quantifiable Concentration for Groups A to D
h*µg/mLGroup A: Normal Renal FunctionGroup B: Mild Renal ImpairmentGroup C: Moderate Renal ImpairmentGroup D: Severe Renal Impairment
Area Under the Concentration-time Curve (AUC(0-t)) of Ucb L059 (LEV) From Baseline to the Last Quantifiable Concentration for Groups A to D165.9996 ± 16.5247.6430 ± 16.9169.3392 ± 16.5212.1193 ± 19.1
PrimaryMaximum Observed Plasma Concentration (Cmax) of Ucb L057 for Groups A to D

Cmax refers to the maximum observed concentration of ucb L057. Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours

Time frame:
From Baseline up to 144 hours post first dose
Reported as:
Geometric mean · µg/mL
Maximum Observed Plasma Concentration (Cmax) of Ucb L057 for Groups A to D
µg/mLGroup A: Normal Renal FunctionGroup B: Mild Renal ImpairmentGroup C: Moderate Renal ImpairmentGroup D: Severe Renal Impairment
Maximum Observed Plasma Concentration (Cmax) of Ucb L057 for Groups A to D0.3620 ± 9.40.7503 ± 25.80.5674 ± 26.01.0640 ± 29.3
PrimaryArea Under the Concentration-time Curve (AUC(0-t)) of Ucb L057 From Baseline to the Last Quantifiable Concentration for Groups A to D

AUC(0-t) refers to the area under the plasma concentration versus time curve, which provides information on the exposure. Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours

Time frame:
From Baseline up to 144 hours post first dose
Reported as:
Geometric mean · h*µg/mL
Area Under the Concentration-time Curve (AUC(0-t)) of Ucb L057 From Baseline to the Last Quantifiable Concentration for Groups A to D
h*µg/mLGroup A: Normal Renal FunctionGroup B: Mild Renal ImpairmentGroup C: Moderate Renal ImpairmentGroup D: Severe Renal Impairment
Area Under the Concentration-time Curve (AUC(0-t)) of Ucb L057 From Baseline to the Last Quantifiable Concentration for Groups A to D5.8607 ± 9.722.5573 ± 45.918.6675 ± 53.457.7773 ± 57.3
PrimaryMaximum Observed Plasma Concentration (Cmax) of Ucb L059 (LEV) for Group E During First Period

Cmax refers to the maximum observed concentration of ucb L059 (Levetiracetam).

Time frame:
From Baseline to 44 hours post first dose
Reported as:
Geometric mean · µg/mL
Maximum Observed Plasma Concentration (Cmax) of Ucb L059 (LEV) for Group E During First Period
µg/mLGroup E: End-stage Renal Disease
Maximum Observed Plasma Concentration (Cmax) of Ucb L059 (LEV) for Group E During First Period18.6810 ± 8.1
PrimaryArea Under the Concentration-time Curve (AUC(0-t)) of Ucb L059 (LEV) From Baseline to 44 Hours for Group E

AUC(0-t) refers to the area under the plasma concentration versus time curve, which provides information on the exposure.

Time frame:
From Baseline to 44 hours post first dose
Reported as:
Geometric mean · h*µg/mL
Area Under the Concentration-time Curve (AUC(0-t)) of Ucb L059 (LEV) From Baseline to 44 Hours for Group E
h*µg/mLGroup E: End-stage Renal Disease
Area Under the Concentration-time Curve (AUC(0-t)) of Ucb L059 (LEV) From Baseline to 44 Hours for Group E462.4883 ± 10.5
PrimaryMaximum Observed Plasma Concentration (Cmax) of Ucb L057 for Group E During First Period

Cmax refers to the maximum observed concentration of ucb L057.

Time frame:
From Baseline to 44 hours post first dose
Reported as:
Geometric mean · µg/mL
Maximum Observed Plasma Concentration (Cmax) of Ucb L057 for Group E During First Period
µg/mLGroup E: End-stage Renal Disease
Maximum Observed Plasma Concentration (Cmax) of Ucb L057 for Group E During First Period8.8435 ± 7.0
PrimaryArea Under the Concentration-time Curve (AUC(0-t)) of Ucb L057 From Baseline to 44 Hours for Group E

AUC(0-t) refers to the area under the plasma concentration versus time curve, which provides information on the exposure.

Time frame:
From Baseline to 44 hours post first dose
Reported as:
Geometric mean · h*µg/mL
Area Under the Concentration-time Curve (AUC(0-t)) of Ucb L057 From Baseline to 44 Hours for Group E
h*µg/mLGroup E: End-stage Renal Disease
Area Under the Concentration-time Curve (AUC(0-t)) of Ucb L057 From Baseline to 44 Hours for Group E230.4393 ± 7.8
SecondaryTotal Amount Excreted in Urine (Ae) of Ucb L059 (LEV) for Groups A to D

Ae refers to the total amount of ucb L059 (Levetiracetam) excreted in urine. Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours

Time frame:
From Baseline up to 144 hours post first dose
Reported as:
Geometric mean · mg
Total Amount Excreted in Urine (Ae) of Ucb L059 (LEV) for Groups A to D
mgGroup A: Normal Renal FunctionGroup B: Mild Renal ImpairmentGroup C: Moderate Renal ImpairmentGroup D: Severe Renal Impairment
Total Amount Excreted in Urine (Ae) of Ucb L059 (LEV) for Groups A to D304.7321 ± 30.3247.6562 ± 12.598.7182 ± 11.974.3761 ± 34.4
SecondaryFraction of Dose Excreted in Urine (fe) of Ucb L059 (LEV) for Groups A to D

fe refers to the fraction of dose excreted in urine of L059 (Levetiracetam). Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours

Time frame:
From Baseline up to 144 hours post first dose
Reported as:
Geometric mean · Percentage of Dose Administered
Fraction of Dose Excreted in Urine (fe) of Ucb L059 (LEV) for Groups A to D
Percentage of Dose AdministeredGroup A: Normal Renal FunctionGroup B: Mild Renal ImpairmentGroup C: Moderate Renal ImpairmentGroup D: Severe Renal Impairment
Fraction of Dose Excreted in Urine (fe) of Ucb L059 (LEV) for Groups A to D60.9464 ± 30.349.5312 ± 12.539.4873 ± 11.929.7504 ± 34.4
SecondaryRenal Clearance (CLR) of Ucb L059 (LEV) for Groups A to D

Renal clearance describes the removal of drug from a volume of plasma in a given unit of time by the kidneys. Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours

Time frame:
From Baseline up to 144 hours post first dose
Reported as:
Geometric mean · L/h
Renal Clearance (CLR) of Ucb L059 (LEV) for Groups A to D
L/hGroup A: Normal Renal FunctionGroup B: Mild Renal ImpairmentGroup C: Moderate Renal ImpairmentGroup D: Severe Renal Impairment
Renal Clearance (CLR) of Ucb L059 (LEV) for Groups A to D1.8622 ± 27.40.9820 ± 22.10.5671 ± 17.60.3417 ± 49.3
SecondaryApparent Total Body Clearance (CL/F) of Ucb L059 (LEV) for Groups A to D

Clearance (expressed as volume/time) describes the removal of drug from a volume of plasma in a given unit of time (drug loss from the body). It indicates the volume of plasma (or blood) from which the drug is completely removed, or cleared, in a given time period. Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours

Time frame:
From Baseline up to 144 hours post first dose
Reported as:
Geometric mean · L/h
Apparent Total Body Clearance (CL/F) of Ucb L059 (LEV) for Groups A to D
L/hGroup A: Normal Renal FunctionGroup B: Mild Renal ImpairmentGroup C: Moderate Renal ImpairmentGroup D: Severe Renal Impairment
Apparent Total Body Clearance (CL/F) of Ucb L059 (LEV) for Groups A to D2.9359 ± 14.81.9826 ± 16.01.4362 ± 15.31.1484 ± 19.1
SecondaryNonrenal Clearance (CLNR) of Ucb L059 (LEV) for Groups A to D

The Non-Renal Clearance (CLNR) describes the removal of drug by organs other than the kidneys. Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours

Time frame:
From Baseline up to 144 hours post first dose
Reported as:
Geometric mean · L/h
Nonrenal Clearance (CLNR) of Ucb L059 (LEV) for Groups A to D
L/hGroup A: Normal Renal FunctionGroup B: Mild Renal ImpairmentGroup C: Moderate Renal ImpairmentGroup D: Severe Renal Impairment
Nonrenal Clearance (CLNR) of Ucb L059 (LEV) for Groups A to D1.0712 ± 50.60.9873 ± 17.40.8636 ± 18.40.7848 ± 17.9
SecondaryTotal Amount Excreted in Urine (Ae) of Ucb L057 for Groups A to D

Ae refers to the total amount of ucb L057 excreted in urine. Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours

Time frame:
From Baseline up to 144 hours post first dose
Reported as:
Geometric mean · mg
Total Amount Excreted in Urine (Ae) of Ucb L057 for Groups A to D
mgGroup A: Normal Renal FunctionGroup B: Mild Renal ImpairmentGroup C: Moderate Renal ImpairmentGroup D: Severe Renal Impairment
Total Amount Excreted in Urine (Ae) of Ucb L057 for Groups A to D83.5936 ± 16.9169.3395 ± 19.093.1346 ± 14.0100.7489 ± 17.8
SecondaryRenal Clearance (CLR) of Ucb L057 for Groups A to D

Renal clearance describes the removal of drug from a volume of plasma in a given unit of time by the kidneys. Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours

Time frame:
From Baseline up to 144 hours post first dose
Reported as:
Geometric mean · L/h
Renal Clearance (CLR) of Ucb L057 for Groups A to D
L/hGroup A: Normal Renal FunctionGroup B: Mild Renal ImpairmentGroup C: Moderate Renal ImpairmentGroup D: Severe Renal Impairment
Renal Clearance (CLR) of Ucb L057 for Groups A to D14.6937 ± 18.36.8015 ± 32.64.6828 ± 45.61.6475 ± 42.0
SecondaryApparent Total Body Clearance (CL/F) of Ucb L059 (LEV) for Group E During First Period

Clearance (expressed as volume/time) describes the removal of drug from a volume of plasma in a given unit of time (drug loss from the body). It indicates the volume of plasma (or blood) from which the drug is completely removed, or cleared, in a given time period. Geometric mean and Coefficient of Variation (CV) was not calculated since the extrapolated part of the AUC was greater than 20 %.

Time frame:
From Baseline to 44 hours post first dose
Reported as:
Median · L/h
Apparent Total Body Clearance (CL/F) of Ucb L059 (LEV) for Group E During First Period
L/hGroup E: End-stage Renal Disease
Apparent Total Body Clearance (CL/F) of Ucb L059 (LEV) for Group E During First Period0.629 (0.500 to 0.801)
SecondaryTime to Reach Maximum Plasma Concentration (Tmax) of Ucb L059 (LEV) for Groups A to D

tmax refers to the time to reach maximum plasma concentration of ucb L059 (Levetiracetam). Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours

Time frame:
From Baseline up to 144 hours post first dose
Reported as:
Median · hours
Time to Reach Maximum Plasma Concentration (Tmax) of Ucb L059 (LEV) for Groups A to D
hoursGroup A: Normal Renal FunctionGroup B: Mild Renal ImpairmentGroup C: Moderate Renal ImpairmentGroup D: Severe Renal Impairment
Time to Reach Maximum Plasma Concentration (Tmax) of Ucb L059 (LEV) for Groups A to D0.500 (0.500 to 2.000)1.000 (0.500 to 2.000)0.500 (0.500 to 1.000)0.500 (0.500 to 1.000)
SecondaryArea Under the Concentration-time Curve (AUC) of Ucb L059 (LEV) From Baseline to Infinite for Groups A to D

AUC(0-t) refers to the area under the plasma concentration versus time curve, which provides information on the exposure. Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours

Time frame:
From Baseline up to 144 hours post first dose
Reported as:
Geometric mean · h*µg/mL
Area Under the Concentration-time Curve (AUC) of Ucb L059 (LEV) From Baseline to Infinite for Groups A to D
h*µg/mLGroup A: Normal Renal FunctionGroup B: Mild Renal ImpairmentGroup C: Moderate Renal ImpairmentGroup D: Severe Renal Impairment
Area Under the Concentration-time Curve (AUC) of Ucb L059 (LEV) From Baseline to Infinite for Groups A to D170.3045 ± 14.8252.1923 ± 16.0174.0764 ± 15.3217.6854 ± 19.1
SecondaryTerminal Half-life (t1/2) of Ucb L059 (LEV) for Groups A to D

Terminal half-life refers to the time it takes for the concentrations to decrease by half. Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours

Time frame:
From Baseline up to 144 hours post first dose
Reported as:
Geometric mean · hours
Terminal Half-life (t1/2) of Ucb L059 (LEV) for Groups A to D
hoursGroup A: Normal Renal FunctionGroup B: Mild Renal ImpairmentGroup C: Moderate Renal ImpairmentGroup D: Severe Renal Impairment
Terminal Half-life (t1/2) of Ucb L059 (LEV) for Groups A to D7.6164 ± 6.912.6214 ± 11.315.5033 ± 17.519.7320 ± 26.5
SecondaryTime to Reach Maximum Plasma Concentration (Tmax) of Ucb L057 for Groups A to D

tmax refers to the time to reach maximum plasma concentration (tmax). Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours

Time frame:
From Baseline up to 144 hours post first dose
Reported as:
Median · hours
Time to Reach Maximum Plasma Concentration (Tmax) of Ucb L057 for Groups A to D
hoursGroup A: Normal Renal FunctionGroup B: Mild Renal ImpairmentGroup C: Moderate Renal ImpairmentGroup D: Severe Renal Impairment
Time to Reach Maximum Plasma Concentration (Tmax) of Ucb L057 for Groups A to D5.000 (2.000 to 8.000)8.000 (6.000 to 12.000)12.000 (8.000 to 12.000)24.000 (12.000 to 24.000)
SecondaryArea Under the Concentration-time Curve (AUC) of Ucb L057 From Baseline to Infinite for Groups A to D

AUC(0-t) refers to the area under the plasma concentration versus time curve, which provides information on the exposure. Geometric mean and CV was not calculated since the extrapolated part of the AUC was greater than 20 %. Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours

Time frame:
From Baseline up to 144 hours post first dose
Reported as:
Median · h*µg/mL
Area Under the Concentration-time Curve (AUC) of Ucb L057 From Baseline to Infinite for Groups A to D
h*µg/mLGroup A: Normal Renal FunctionGroup B: Mild Renal ImpairmentGroup C: Moderate Renal ImpairmentGroup D: Severe Renal Impairment
Area Under the Concentration-time Curve (AUC) of Ucb L057 From Baseline to Infinite for Groups A to D8.176 ± 032.401 (28.910 to 38.917)27.441 (16.472 to 41.184)63.126 (48.016 to 171.348)
SecondaryTerminal Half-life (t1/2) of Ucb L057 for Groups A to D

Terminal half-life refers to the time it takes for the concentrations to decrease by half. Group A: Baseline to 72 hours; Group B: Baseline to 96 hours; Group C: Baseline to 120 hours; Group D: Baseline to 144 hours

Time frame:
From Baseline up to 144 hours post first dose
Reported as:
Median · hours
Terminal Half-life (t1/2) of Ucb L057 for Groups A to D
hoursGroup A: Normal Renal FunctionGroup B: Mild Renal ImpairmentGroup C: Moderate Renal ImpairmentGroup D: Severe Renal Impairment
Terminal Half-life (t1/2) of Ucb L057 for Groups A to D12.351 (11.348 to 15.310)19.030 (17.331 to 19.903)20.303 (19.681 to 23.569)26.769 (17.249 to 33.348)
SecondaryTime to Reach Maximum Plasma Concentration (Tmax) of Ucb L059 (Levetiracetam) for Group E During First Period

tmax refers to the time to reach the maximum plasma concentration of ucb L059 (Levetiracetam).

Time frame:
From Baseline to 44 hours post first dose
Reported as:
Median · hours
Time to Reach Maximum Plasma Concentration (Tmax) of Ucb L059 (Levetiracetam) for Group E During First Period
hoursGroup E: End-stage Renal Disease
Time to Reach Maximum Plasma Concentration (Tmax) of Ucb L059 (Levetiracetam) for Group E During First Period0.720 (0.430 to 0.980)
SecondaryArea Under the Concentration-time Curve (AUC) of Ucb L059 (LEV) From Baseline to Infinite for Group E

AUC(0-t) refers to the area under the plasma concentration versus time curve, which provides information on the exposure. Geometric mean and CV was not calculated since the extrapolated part of the AUC was greater than 20 %.

Time frame:
From Baseline to 140 hours post first dose
Reported as:
Median · h*µg/mL
Area Under the Concentration-time Curve (AUC) of Ucb L059 (LEV) From Baseline to Infinite for Group E
h*µg/mLGroup E: End-stage Renal Disease
Area Under the Concentration-time Curve (AUC) of Ucb L059 (LEV) From Baseline to Infinite for Group E794.588 ± 10.5
SecondaryTerminal Half-life (t1/2) of Ucb L059 (LEV) for Group E During First Period

Terminal half-life refers to the time it takes for the concentrations to decrease by half. Geometric mean and CV was not calculated since the extrapolated part of the AUC was greater than 20 %.

Time frame:
From Baseline to 44 hours post first dose
Reported as:
Median · hours
Terminal Half-life (t1/2) of Ucb L059 (LEV) for Group E During First Period
hoursGroup E: End-stage Renal Disease
Terminal Half-life (t1/2) of Ucb L059 (LEV) for Group E During First Period34.669 (29.227 to 38.648)
SecondaryTime to Reach Maximum Plasma Concentration (Tmax) of Ucb L057 for Group E During First Period

tmax refers to the time to reach maximum plasma concentration (tmax).

Time frame:
From Baseline to 44 hours post first dose
Reported as:
Median · hours
Time to Reach Maximum Plasma Concentration (Tmax) of Ucb L057 for Group E During First Period
hoursGroup E: End-stage Renal Disease
Time to Reach Maximum Plasma Concentration (Tmax) of Ucb L057 for Group E During First Period44.020 (44.000 to 44.030)
SecondaryHemodialysis Clearance (CLD) of Ucb L059 (LEV) During First Dialysis for Group E

Calculated by the Arterio - Venous difference method and cumulative dialysate method.

Time frame:
From 44 hours to 48 hours post first dose
Reported as:
Geometric mean · mL/min
Hemodialysis Clearance (CLD) of Ucb L059 (LEV) During First Dialysis for Group E
mL/minGroup E: End-stage Renal Disease
Hemodialysis Clearance (CLD) of Ucb L059 (LEV) During First Dialysis for Group E113.9665 ± 8.5
SecondaryUltrafiltration Clearance (CLUF) of Ucb L059 (LEV) During First Dialysis for Group E

Calculated by the Arterio - Venous difference method and cumulative dialysate method.

Time frame:
From 44 hours to 48 hours post first dose
Reported as:
Geometric mean · mL/min
Ultrafiltration Clearance (CLUF) of Ucb L059 (LEV) During First Dialysis for Group E
mL/minGroup E: End-stage Renal Disease
Ultrafiltration Clearance (CLUF) of Ucb L059 (LEV) During First Dialysis for Group E1.3271 ± 32.5
SecondaryHemodialysis Clearance (CLHD) of Ucb L059 (LEV) During First Dialysis for Group E

Calculated according: CLHD=CLD+CLUF.

Time frame:
From 44 hours to 48 hours post first dose
Reported as:
Geometric mean · mL/min
Hemodialysis Clearance (CLHD) of Ucb L059 (LEV) During First Dialysis for Group E
mL/minGroup E: End-stage Renal Disease
Hemodialysis Clearance (CLHD) of Ucb L059 (LEV) During First Dialysis for Group E115.3702 ± 8.1

Adverse events

Collected over Treatment-Emergent Adverse Events were reported from Day 1 up to Day 8 (+2 days) for Group A to D and from Day 1 up to Day 10 (+2 days) for Group E.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group A: Normal Renal Function—0/6 (0%)0/6 (0%)
Group B: Mild Renal Impairment—0/6 (0%)2/6 (33.3%)
Group C: Moderate Renal Impairment—0/6 (0%)0/6 (0%)
Group D: Severe Renal Impairment—0/6 (0%)1/6 (16.7%)
Group E: End-stage Renal Disease—1/6 (16.7%)2/6 (33.3%)
Most frequent serious events
Most frequent serious events
EventGroup A: Normal Renal FunctionGroup B: Mild Renal ImpairmentGroup C: Moderate Renal ImpairmentGroup D: Severe Renal ImpairmentGroup E: End-stage Renal Disease
PneumoniaInfections and infestations0/60/60/60/61/6
Acute respiratory distress syndromeRespiratory, thoracic and mediastinal disorders0/60/60/60/61/6
Shunt malfunctionInjury, poisoning and procedural complications0/60/60/60/61/6
Most frequent other events
Showing 10 of 11
Most frequent other events
EventGroup A: Normal Renal FunctionGroup B: Mild Renal ImpairmentGroup C: Moderate Renal ImpairmentGroup D: Severe Renal ImpairmentGroup E: End-stage Renal Disease
GingivitisGastrointestinal disorders0/61/60/60/60/6
ToothacheGastrointestinal disorders0/61/60/60/60/6
PyrexiaGeneral disorders0/61/60/60/60/6
NasopharyngitisInfections and infestations0/60/60/61/60/6
Postoperative wound complicationInjury, poisoning and procedural complications0/60/60/60/61/6
White blood cell count increasedInvestigations0/60/60/60/61/6
Muscle spasmsMusculoskeletal and connective tissue disorders0/60/60/60/61/6
DizzinessNervous system disorders0/60/60/60/61/6
CoughRespiratory, thoracic and mediastinal disorders0/60/60/60/61/6
Productive coughRespiratory, thoracic and mediastinal disorders0/60/60/60/61/6

Baseline characteristics

The Baseline Analysis Population refers to the Pharmacokinetic Per Protocol Set (PK-PPS) which consists of all subjects included in the Safety Set (SS), who also had a sufficient number of bioanalytical assessments (plasma or urine) to calculate reliable estimates for the PK parameters.

Age, Continuous
Age, Continuous(years)Group A: Normal Renal FunctionGroup B: Mild Renal ImpairmentGroup C: Moderate Renal ImpairmentGroup D: Severe Renal ImpairmentGroup E: End-stage Renal DiseaseTotal
Mean61.7 ± 2.667.5 ± 5.069.3 ± 6.155.8 ± 17.168.8 ± 7.964.6 ± 10.0
Age, Customized
Age, Customized(participants)Group A: Normal Renal FunctionGroup B: Mild Renal ImpairmentGroup C: Moderate Renal ImpairmentGroup D: Severe Renal ImpairmentGroup E: End-stage Renal DiseaseTotal
20 - <65 years5314215
>=65 years1352415
Sex: Female, Male
Sex: Female, Male(Participants)Group A: Normal Renal FunctionGroup B: Mild Renal ImpairmentGroup C: Moderate Renal ImpairmentGroup D: Severe Renal ImpairmentGroup E: End-stage Renal DiseaseTotal
Female100001
Male5666629
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Group A: Normal Renal FunctionGroup B: Mild Renal ImpairmentGroup C: Moderate Renal ImpairmentGroup D: Severe Renal ImpairmentGroup E: End-stage Renal DiseaseTotal
Asian6666630
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Group A: Normal Renal FunctionGroup B: Mild Renal ImpairmentGroup C: Moderate Renal ImpairmentGroup D: Severe Renal ImpairmentGroup E: End-stage Renal DiseaseTotal
Japanese6666630
Weight
Weight(kilogram)Group A: Normal Renal FunctionGroup B: Mild Renal ImpairmentGroup C: Moderate Renal ImpairmentGroup D: Severe Renal ImpairmentGroup E: End-stage Renal DiseaseTotal
Mean60.95 ± 10.9774.28 ± 4.1463.07 ± 12.4958.70 ± 6.1062.20 ± 5.4163.84 ± 9.62
Height
Height(centimeters)Group A: Normal Renal FunctionGroup B: Mild Renal ImpairmentGroup C: Moderate Renal ImpairmentGroup D: Severe Renal ImpairmentGroup E: End-stage Renal DiseaseTotal
Mean161.73 ± 9.05165.65 ± 3.11163.72 ± 5.64164.50 ± 6.34162.38 ± 3.41163.60 ± 5.68
08

Study locations

2 sites
  • 1
    Fukuoka, Japan
  • 2
    Ibaraki, Japan
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Nov 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2014, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2011
First posted
Dec 13, 2011
Start
Nov 2011
Primary completionActual
Nov 2012
CompletionActual
Nov 2012
Results first posted
Jan 10, 2014
Last update
Feb 10, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01491113
Lead sponsor
UCB Pharma
Collaborators
Parexel
Responsible party
Sponsor
First posted
Dec 13, 2011
Start date
Nov 2011
Primary completion
Nov 2012
Completion
Nov 2012
Results posted
Jan 10, 2014
Last update
Feb 10, 2014

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levetiracetam

Start the discussion